MedTrace Logo

Validation of Fore-Sight Cerebral & Tissue Oximeter Saturation Measurements on Neonates ≤ 5 kg

NCT02017652 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2017-10-09

No results posted yet for this study

Summary

CASMED, INC. wishes to validate the next generation FORE-SIGHT-II (FS-II) NIRS tissue oximeter monitor for neonatal brain and somatic tissue oxygen saturation (StO2) measurements. This monitor was recently FDA cleared for use on adult subjects.

Conditions

  • Bowel Motility

Sponsors & Collaborators

  • Sharp HealthCare

    lead OTHER

Principal Investigators

  • Anuup Katheria, MD · Sharp Mary Birch Hospital for Women & Newborns

Eligibility

Max Age
7 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02017652 on ClinicalTrials.gov